When we cast our minds back to the tempestuous days at the height of the COVID-19 pandemic, two names are now forever etched in our collective memory: Katalin Karikó and Drew Weissman. In an announcement that resonated around the globe, these two esteemed scientists were lauded as the Physiology & Medicine 2023 Nobel Prize laureates.
Dr. Karikó, a daughter of a Hungarian butcher, and Dr. Weissman, a committed physician and virologist, weren’t always bound for the annals of history. Their collaboration sparked from a chance meeting beside a mundane piece of office equipment—a photocopier—at the University of Pennsylvania in 1998. But where others saw a functional but forgettable machine, their keen scientific minds recognized an opportunity for collaboration, a chance to breach the barriers of conventional wisdom and orthodoxy.
Karikó’s lifelong dalliance with mRNA, a molecule that was widely dismissed in clinical contexts, proved central to their groundbreaking work. mRNA, the courier of genetic instructions from DNA to the cellular machinery that produces proteins, was long considered too fragile and unstable for therapeutic use. But Karikó and Weissman, braving skepticism and the scorn of the broader scientific community, were undeterred.
They embarked upon a scientific odyssey, navigating a labyrinth of failed experiments and elusive answers. mRNA was sensitive, evoking an immune response that rendered it impotent for therapeutic use. But in this seemingly insurmountable challenge, Karikó and Weissman found not a terminus, but a new beginning.
In the quiet climes of their lab, a revelation emerged. By making a nuanced chemical modification to the mRNA, they circumvented the immune response, ushering in a new dawn for vaccine technology. Published in 2005, their work was first met with indifference, relegated to the annals of a niche journal after facing rejection from powerhouses like Nature and Science.
Yet, the resonance of their discovery caught the discerning eyes of biotech firms Moderna and BioNTech, charting a new trajectory not just for Karikó and Weissman, but for humanity at large.
Karikó’s journey from the outskirts of scientific recognition to the pinnacle of acclaim mirrors the extraordinary impact of mRNA technology. With the advent of COVID-19, their discovery proved instrumental. The Pfizer-BioNTech and Moderna vaccines, anchored in their pioneering work, have been administered billions of times globally, a testament to the resilience and potency of mRNA technology.
Weissman, who once toiled in the esteemed corridors of Anthony S. Fauci’s lab, alongside Karikó, has now etched his name in the annals of history. The duo’s indefatigable spirit, their unyielding conviction in the face of skepticism, is encapsulated in Weissman’s words on that momentous morning when the Nobel call arrived. “It was a wonderful moment.”
“There was a great deal of skepticism early on. They didn’t have a lot of support, but they persisted,” said Anthony S. Fauci, a professor at Georgetown University and the former director of the National Institute of Allergy and Infectious Diseases. “It was an amazingly productive collaboration.”
However, Karikó and Weissman are not resting on their laurels. Their gaze is firmly fixed ahead, with Weissman articulating aspirations to extend the unprecedented potential of mRNA to tackle diseases like sickle cell—an affliction ravaging communities beyond the affluent enclaves of the Western world.
Karikó’s affiliation with BioNTech, a then little-known start-up that has now ascended to global prominence, mirrors the underdog narrative that defines her and Weissman’s journey. The 13th woman to receive the esteemed Nobel recognition in Physiology or Medicine, Karikó stands as a beacon of inspiration, illuminating the paths for aspiring female scientists navigating the often tumultuous waters of a field where gender disparity still lurks.
In the echoing halls of the Nobel Assembly, secretary-general Thomas Perlmann’s words encapsulate the epochal significance of Karikó and Weissman’s work. A discovery not just transformative for its inherent innovation, but for its multi-faceted impact across the diverse realms of science.
Click on this link to read this article in French version